— The majority of patients, 51.9% (378/728), entered with or achieved complete disease clearance (vIGA-AD™=0) in the 48-week ADORING 3 open-label LTE study. — — Most patients, 81.6% (594/728), entered with or achieved clear or almost clear skin (vIGA-AD=0 or 1) with VTAMA cream, 1% in the ADORING 3 open-label LTE study. — — Patients […]
Search Results for: VTAMA® (tapinarof) cream, 1%